
Human endometrial mesenchymal stem cells exhibit intrinsic anti-tumor properties on human epithelial ovarian cancer cells.

Shixia Bu¹, Qian Wang¹, Qiuwan Zhang¹, Junyan Sun¹, Biwei He¹, Charlie Xiang², Zhiwei Liu^{1*} and Dongmei Lai^{1*}


¹The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200030, China

²State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 31000

Correspondence information: Professor Dongmei Lai & Zhiwei Liu, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200030, China. Telephone: 021-64070434; Fax: 86-21-64074642; e-mail: laidongmei@hotmail.com and liuzhiwei@hotmail.com.



Supplementary Figure S1. The anti-tumor properties of EnSCs against EOC cells through the paracrine pathway is specific. **(A):** CCK-8 cell viability assay was used to test the effects of EnSC-CM on the viability of non-malignant cells (293FT and hUVECs) at the 48th hour (n=3; performed in triplicate). **(B):** CCK-8 cell viability assay was used to test the effects of 293FT-CM and hUVEC-CM on the viability of EOC cells at the 48th hour (n=3; performed in triplicate). All data were shown as means \pm SEM. Ordinary one-way ANOVA was used for statistic analysis. *p-value<0.05; **p-value<0.01; ***p-value<0.001.



Supplementary Figure S2. A schematic diagram showed that EnSCs exhibited antitumor effects on EOC cells through inhibiting AKT phosphorylation and promoting nucleus translocation of FoxO3a in EOC cells in vivo and in vitro through both paracrine way and direct cell-cell contact way. The EnSC-induced transcriptional activity of FoxO3a induces mitochondria dysfunction, cellular growth inhibition, G0/G1 cell cycle arrest, apoptosis and inhibition of pro-angiogenetic ability of EOC cells in vivo and in vitro.

Supplementary Table S1

Primers for real-time PCR analysis of human genes.

Gene	Primer sequence	Product size
		(bp)
18s RNA	Forward: 5'-CGTTGATTAAGTCCCTGCCCTT-3'	137
	Reverse: 5'-TCAAGTTCGACCGTCTTCTCAG-3'	
PCNA	Forward: 5'-TTCCTGTGCAAAAGACGGAG-3'	197
	Reverse: 5'-TCACCGTTGAAGAGAGTGGA-3'	
Ki-67	Forward: 5'-GAGGCAAATCATCCGAACCC-3'	181
	Reverse: 5'-TTATTTTGGCGTCTGGAGCG-3'	
Bcl-2	Forward: 5'-ATGTGTGTGGAGAGCGTCAACC-3'	196
	Reverse: 5'-TGAGCAGAGTCTTCAGAGACAGCC-3'	
Bax	Forward: 5'-AAGAAGCTGAGCGAGTGTCT-3'	184
	Reverse: 5'-TGGCAAAGTAGAAAAGGGCG-3'	
Bcl-x _L	Forward: 5'-AGTTCAGCACCACCCTAGTC-3'	212
	Reverse: 5'-GCTGTTCCTGATAGCTCCCT-3'	
Bad	Forward: 5'-GAGTGACGAGTTTGTGGACT-3'	178
	Reverse: 5'-TTTCGGGATGTGGAGCGAA-3'	
AKT1	Forward: 5'-TCGGCAAGGTGATCCTGGTGAA-3'	184
	Reverse: 5'-CGGTCGTGGGTCTGGAAAGAGT-3'	
AKT2	Forward: 5'-AGGAGATGGAAGTGGCGGTCAG-3'	270
	Reverse: 5'-GGTCGTGGGTCTGGAAGGCATA-3'	
AKT3	Forward: 5'-GCAAAGGATGAAGTGGCACACA-3'	182
	Reverse: 5'-TCCTCAGAGAACACCCGCTCTC-3'	

PTEN	Forward: 5'-GAGGCAGCCGTTCGGAGGATTA-3'	196
	Reverse: 5'-ATGGCTCTGGACTTGGCGGTAG-3'	